In Germany, Next-Generation Sequencing (NGS) benefits from a well-trained workforce and comprehensive infrastructure, fostering routine utilization and implementation in healthcare and research. The availability of a broad cancer panel enhances accurate diagnosis and treatment planning. There’s limited reimbursement for NGS but availability for liquid biopsy, though funding for the reimbursement process is insufficient.

Clinical labs and institutions follow ISO standards, update clinical guidelines regularly, and utilize both internal and external guidelines, along with quality assessments. Germany demonstrates a strong healthcare workforce trained in NGS, ensuring efficient testing. Collaborations are actively pursued, yet routine data sharing remains uncommon, despite the emphasis on data security and integration with electronic health records.

For a more detailed analysis, the complete factsheet below provides comprehensive insights.